AI assistant
Moleculin Biotech, Inc. — Director's Dealing 2022
Jun 23, 2022
34881_dirs_2022-06-22_2f292326-7850-44ea-94c4-093e03f360f2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2022-06-20
Reporting Person: Cermak Elizabeth (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-20 | Stock option (right to buy) | $1.49 | A | 23333 | Acquired | 2032-06-20 | Common Stock (23333) | Direct |
| 2022-06-20 | Stock option (right to buy) | $1.49 | A | 15000 | Acquired | 2032-06-20 | Common Stock (15000) | Direct |
Footnotes
F1: The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
F2: The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date.
F3: The options were issued in connection with the reporting person's Board of Director service to the Company.